Routine mammograms caught breast cancers neither woman could feel
A routine mammogram found breast cancer in two women who felt healthy, had no warning signs, and did not detect anything unusual during self-examination. Their stories cut directly against a common and dangerous assumption in screening: that a person will usually sense when something is wrong before imaging does.
Prof Linda Flores, from the University of Oxford, was diagnosed at 52 after a mammogram in 2024. She had no family history of cancer and says she felt remarkably well at the time. The tumour measured 2 cm and was hidden behind her nipple, a location that made it difficult to detect by touch alone. A biopsy later confirmed the diagnosis after the scan had already raised concern.
The clinical lesson is blunt. Symptoms are not required for early breast cancer detection.
Flores described the diagnosis as a shock because nothing in her day-to-day health had hinted at malignancy. Her experience is a reminder that cancers can grow quietly in tissue planes where physical examination has limited reach, especially when lesions sit deep or are obscured by normal anatomy. A mammogram is designed to identify abnormalities before they declare themselves as a lump, pain, skin change, or discharge. In a setting like this, screening is not an abstract public health exercise; it is the first line of defense against an occult tumour advancing unnoticed.
Enda Kenneally had a similar experience in March, when a routine mammogram detected a 2.5 cm lump buried deep in her breast. The cancer was found at stage one. She recalled doing the checks many women are taught to perform and finding nothing untoward. Without screening, the lesion would have continued to grow.
These two cases illustrate why self-checks, while still part of public awareness, cannot replace imaging-based screening. Palpation is limited by tumour size, position, breast density, and the ordinary variability of normal breast tissue. A lesion tucked behind the nipple or located deep in the breast can remain clinically silent until it has expanded enough to become easier to feel or until it has already moved into a more advanced stage. Mammography is built to detect those hidden changes earlier, before the window for simpler treatment narrows.
Fear, delay, and the low yield of screening that still saves lives
A recent Nuffield Health survey found that more than one in nine women have avoided having a breast lump or abnormality checked. Pain during the mammogram and anxiety were among the reasons given. The reluctance is understandable, but it collides with the mechanics of screening: most women screened will not have cancer, yet the small fraction who do may be the ones who benefit most from finding it early.
Senior radiographer Lorna Goodwin, from Nuffield’s The Manor Hospital in Oxford, said mammograms pick up concerns in only four out of every 100 women screened. The number is modest, and that is precisely why the process is valuable. Screening must examine many people to identify the few whose cancers would otherwise remain hidden. The burden of testing 100 women is the price of catching the four with an abnormality that could alter survival, treatment intensity, and long-term outcomes.
In practical terms, that means the discomfort of the scan and the anxiety around waiting for results cannot be weighed only against the immediate experience in the imaging room. The more relevant comparison is between a brief, uncomfortable appointment and the possibility of finding a cancer while it is still localized, operable, and more likely to be treated successfully. When disease is detected at stage one, the clinical pathway is generally very different from one in which the tumor has had months or years to enlarge unnoticed.
The NHS invites women for routine screening every three years from age 50 to 71, though a mammogram can be requested at any time. That schedule reflects a balance between access, resource use, and the fact that risk rises with age. It also means women who feel well may still be the ones most in need of screening, since absence of symptoms can create false reassurance. Flores put that problem plainly when she said that if she had relied on her instincts that she was healthy, she might not be here today.
The biology behind that warning is straightforward. Breast cancer can develop in tissue long before it produces a sensation, especially when the tumor is small, deep, or masked by surrounding structures. Imaging can identify microcalcifications, masses, and architectural changes that hands cannot feel. By the time a patient notices a change on her own, the disease may already have crossed into a different clinical phase.
These accounts do not suggest that every woman needs urgent imaging outside established pathways. They do show why attendance at scheduled screening matters, even for people who feel well, have no family history, and perform self-checks carefully. The cancers described here were not announced by pain or a palpable lump. They were found because imaging looked where the hands could not.
For clinicians and patients alike, the final concern is not theoretical. Missed screening can mean a tumour remains hidden until it becomes larger, more complex, and harder to treat. The women who came forward in Oxford reached diagnosis by chance only in the sense that they accepted a scan they did not feel they needed. Their experience leaves a narrow but concrete question hanging over every delayed appointment: how many other cancers are sitting silently behind a false sense of health?